Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Sees Significant Decline in Short Interest

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) was the recipient of a large drop in short interest during the month of December. As of December 15th, there was short interest totaling 11,067 shares, a drop of 45.3% from the November 30th total of 20,224 shares. Currently, 0.2% of the company’s shares are sold short. Based on an average daily trading volume, of 33,204 shares, the days-to-cover ratio is presently 0.3 days. Based on an average daily trading volume, of 33,204 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.2% of the company’s shares are sold short.

Matinas Biopharma Stock Performance

MTNB stock traded down $0.02 on Monday, reaching $0.60. The company’s stock had a trading volume of 51,158 shares, compared to its average volume of 304,458. The firm has a market cap of $3.85 million, a PE ratio of -0.17 and a beta of 1.33. The business has a fifty day simple moving average of $1.02 and a two-hundred day simple moving average of $1.28. Matinas Biopharma has a 12-month low of $0.47 and a 12-month high of $3.09.

Matinas Biopharma (NYSEAMERICAN:MTNB) last posted its earnings results on Monday, November 10th. The company reported ($0.40) EPS for the quarter.

Matinas Biopharma Company Profile

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.